Hyderabad, Mar 31 (UNI) Suven Life Sciences Ltd has been granted patents for two of its New Chemical Entities (NCEs), for the treatment of disorders associated with neurodegenerative diseases, in Mexico and Korea.
In a statement here today, company CEO Venkat Jasti said the patents, valid until 2023, were exclusive intellectual property of Suven, achieved through exclusive internal discovery research.
''Our drug candidates, being developed for CNS disorders, targets an 18 billion Dollars potential market globally,'' he said.
The granted claims of the patents included the class of selective 5-HT compounds, invented and being developed as therapeutic agents by Suven, which were useful in the treatment of cognitive impairment associated with neurodegenerative disorders like attention-deficient hyperactivity, Alzheimer's, Parkinsons, Schizophrenia and Huntington's.
UNI VA SJ 1330